Grail's Share Price Continues to Decline Amid Unmet Trial Endpoint

Grail (NASDAQ: GRAL) has seen its share price fall by over 20% in 2026 following the release of disappointing top-line results from a three-year trial for its multicancer early detection test, Galleri. The failure to meet the primary endpoint raised concerns about FDA approval and insurance coverage prospects.

By Lee Samaha, The Motley Fool Mon, May 25, 2026 at 3:20 PM GMT+3 5 min read · Yahoo Finance · May 25, 2026, 12:20 UTC

Grail's Share Price Continues to Decline Amid Unmet Trial Endpoint

Tickers: $GRAL

Topics: biotech cancer detection stock performance

Read the full article at Yahoo Finance

More World news

IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC